Trial Profile
A Follow-Up Study to Add Whole Brain Radiotherapy (WBRT) to Standard Temozolomide Chemo-Radiotherapy in Newly Diagnosed Glioblastoma (GBM) Treated With 4 Weeks of Continuous Infusion Plerixafor
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 17 Apr 2023
Price :
$35
*
At a glance
- Drugs Plerixafor (Primary) ; Temozolomide
- Indications Glioblastoma; Glioma; Gliosarcoma; Primitive neuroectodermal tumours
- Focus Therapeutic Use
- 13 Apr 2023 Planned primary completion date changed from 1 Jan 2023 to 26 Jan 2024.
- 07 Jul 2022 Planned End Date changed from 11 Jan 2027 to 1 Jul 2027.
- 07 Jul 2022 Planned primary completion date changed from 11 Jul 2022 to 1 Jan 2023.